The present study uses data from the Prenatal Determinants of Schizophrenia (PDS) Study to derive age-and sex-specific estimates of incidence and cumulative risk for DSM-FV schizophrenia. Although not designed as an incidence study, the PDS Study uses both a well-defined population under continuous followup and DSM-IV diagnoses. The originating cohort was established in Alameda County, California, during 1959-1967 and yielded 12,094 cohort members followed from 1981 to 1997 during the principal ages at risk for schizophrenia. Survival analytic techniques showed that schizophrenia incidence rates per 10,000 person-years for men were 9.4 for ages 15-19; 5.6 for ages 20-24; 33 for ages 25-29; and 0.9 for ages 30-34. Schizophrenia incidence rates per 10,000 person-years for women were 1.6 for ages 15-19; 13 for ages 20-24; and 4.1 for ages 25-29. The cumulative risk for schizophrenia by age 38 was 0.93 percent for men and 035 percent for women. These estimates of incidence rates and risk were higher than those in traditional incidence studies but similar to recent Findings in other cohorts. Possible explanations for the apparently high rates of disorder include chance, design effects, and true variation in risk over time and place. Keywords: Schizophrenia, incidence, cumulative risk.
This article uses the data from the Prenatal Determinants of Schizophrenia Study (Susser et al., this issue) to derive age-and sex-specific estimates of the incidence and cumulative risk of schizophrenia. Incidence and cumulative risk are of vital interest, not only to researchers, but also to patients, family members, clinicians, and policy makers. Yet few contemporary studies have been able to report them for DSM-IV schizophrenia (American Psychiatric Association 1994) in a well-defined population. To our knowledge, no previous study from the United States has done so.
Incidence is a crucial piece of evidence in the investigation of disease etiology; variations in incidence across place and time provide important clues. With respect to schizophrenia, recent reports of an elevated risk of schizophrenia among the urban born compared with the rural born (Torrey and Bowler 1990; Takei et al. 1995; Marcelis et al. 1998; Mortensen et al. 1999 ) as well as declining incidence over time (Munk-Jorgensen 1987; Der et al. 1990; Takei et al. 1996; Suvisaari et al. 1999 ) call for explanation. Furthermore, evidence of increased risk of schizophrenia in association with factors demonstrating temporal and geographic variation (e.g., prenatal flu and prenatal nutrition [Susser et al. 1999] ) and increased risk in offspring of migrants (Harrison et al. 1988; Castle et al. 1991) underscores the importance of examining variations in incidence.
While incidence estimation is crucial to questions of etiology, an incidence rate is a complex indicator. Therefore, the cumulative risk of disorder is most often of interest to patients and their families, clinicians, and policy makers. Cumulative risk estimates the probability of an individual developing schizophrenia within a specified period. The ease of interpretation contributes to the importance of estimating this risk.
The present study adds to a developing line of research on incidence and cumulative risk of schizophrenia. Although not designed as an incidence study, the PDS Study uses a well-defined population under continuous followup and DSM-IV diagnoses. Implementing survival data analytic techniques allows the estimation of age-and sex-specific incidence and cumulative risk in the cohort. then discuss protocols for screening, which led to the identification of 183 potential cases, and those for diagnostic assessment, which resulted in the diagnosis of 71 SSD cases, including 43 cases of schizophrenia.
Registries used in ascertainment Cohort members treated for psychiatric disorders during membership in the Health Plan were ascertained using computerized registries. The registries contain all treatments provided by the Health Plan or paid for by the Health Plan. These data were available from January 1, 1981, to December 31, 1997. The age of cohort members ranged from 13 to 38 over this period (table 1) .
The main registries providing treatment information were the inpatient registry (established 1981) , the outpatient registry (established 1981) , and the pharmacy registry (established 1992) . The inpatient registry data base maintained records of psychiatric admissions at Health Plan hospitals and Health Plan referrals to non-Health Plan hospitals. The outpatient registry included contacts for outpatient psychiatric care in Health Plan clinics. This registry was commenced at Health Plan clinics at different times, depending upon the clinic; ICD-9 diagnoses were added to this registry beginning in 1995. The pharmacy registry included outpatient pharmacy utilization records beginning in 1992.
Screening. The research protocol for screening of potential cases varied by registry. The hospitalization registry screening identified PDS Study cohort members hospitalized with ICD-9 295, 296, 297, 298, and 299 diagnoses as well as those hospitalized for psychiatric reasons with no diagnosis recorded in the data base. Cases were excluded if an ICD-9 inpatient treatment diagnosis was present and not among the targeted codes. Those cases identified as having appropriate diagnostic codes were further screened by chart review. For this purpose, medical and psychiatric records, including intake assessments, physical examinations, progress notes, laboratory results, and discharge summaries, were collected on these individuals. Standardized medical and psychiatric record abstractions and narrative summaries were produced by trained chart reviewers with research degrees, clinical degrees, or both. One of two research psychiatrists with extensive diagnostic experience rated the abstracted records using a standardized protocol as "probable psychosis," "possible psychosis," "no psychosis," or "not enough information to rate" based on the presence or absence of specific psychotic symptoms. The screening of hospitalized cases led to the identification of 144 cohort members rated as "probable," "possible," or "not enough information" by either of the two raters. These 144 potential cases were targeted for direct diagnostic interview.
Outpatient registry screening identified cohort members with ICD-9 diagnoses in the registry of 295, 297, 298, or 299. All those meeting these criteria were considered potential cases and targeted for diagnostic interview. The pharmacy registry screening identified cohort members treated with antipsychotic medication. All those with a qualifying medication history were considered potential cases and targeted for diagnostic interview. It should be noted that ascertainment of potential cases from these registries was incomplete because diagnostic and pharmacy data were not available in the 1980s. Thirty-nine subjects identified in the outpatient or pharmacy registries were targeted for diagnostic interview.
Over all inpatient and outpatient registries, screening procedures identified 183 potential cases to be pursued for diagnostic interview.
Location of potential cases for diagnostic interview. A search of State death certificate files identified 13 deaths among the 183 potential cases targeted for diagnosis. All living potential cases (n = 170) were sought for interview. Contact was established with 146 (86%) of the surviving potential cases. Among those contacted, 39 (26.7%) could not be directly interviewed (32 refused, and 7 were unavailable for other reasons). A total of 107 potential cases completed the face-to-face diagnostic interview; those who could not be interviewed (including the deceased, those who could not be contacted, those who refused, and those who were unavailable) were diagnosed by chart review.
Diagnosis. Diagnostic interviews (n = 107) were conducted by clinicians with a minimum of a master's degree. The Diagnostic Interview for Genetic Studies was used as the diagnostic instrument (Nurnberger et al. 1994) . The interviewer provided a written narrative of the interview, which integrated information from the diagnostic assessment and the medical records and included the interviewer's DSM-IV diagnosis. Interview materials were independendy reviewed by three members of a rotating group of primary diagnosticians; each recorded a diagnostician diagnosis. Each case was reviewed in a conference call that included three diagnosticians, the interviewer, and the Oakland study director, a consensus DSM-IV diagnosis was assigned.
Those who could not be interviewed (n = 76) were diagnosed in accord with DSM-IV criteria by review of psychiatric and medical chart abstracts described above in the Screening section. Chart diagnoses were completed on 75 (one chart was unavailable) by one of two research psychiatrists. The potential cases were assessed for the likelihood of schizophrenia spectrum psychosis: "definitely present," "probably present," "probably not present," and "definitely not present" Those rated as having "definite" or "probable" spectrum psychosis were assigned a best estimate diagnosis. Best estimate diagnoses included "none," "definitely schizophrenia," "probably schizophrenia," "definitely schizoaffective," "probably schizoaffective," and "other schizophrenia spectrum psychosis." For present purposes, schizophrenia was defined to include a best estimate diagnosis of definite schizophrenia or probable schizophrenia; SSD was defined to include best estimate diagnoses of definite schizophrenia, probable schizophrenia, definite schizoaffective disorder, probable schizoaffective disorder, and other schizophrenia spectrum psychosis. Chart reviews did not assess personality disorders and thus did not include schizotypal personality disorder among die diagnoses encompassed by SSD.
Seventy-one cases of SSD were identified either by full diagnostic assessment (n = 44) or chart review (n = 27). Specific diagnoses included 43 cases of schizophrenia, 17 cases of schizoaffective disorder, and 11 cases of other spectrum disorder (schizotypal personality disorder, psychosis not otherwise specified, and delusional disorder).
Age at Onset Age at onset of disorder was defined as the age at "index treatment 1 ' in the Health Plan data base, that is, date of first hospitalization for those with a history of psychiatric hospitalization, or date of first outpatient treatment for those with no Health Plan record of psychiatric hospitalization.
Ages at Risk and Age at Case Ascertainment The age range of risk for the onset of SSD, by study definition, begins at age 15 and ends at 38, the maximum age observed at the end of followup. This period encompasses the principal ages of risk for first episode schizophrenia. A previous study estimated that 90 percent of cases among men and 78 percent of cases among women will have their onset by age 40 (Hambrecht et al. 1992) .
Because of the fit between study period (1981-1997) and birth years of participants (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (table 1) , completeness of followup over ages 15 to 38 varied by birth year. However, all cohort members experienced their 21st through 30th years of age within the study period.
Those born between 1965 and 1967 were 13-15 years old at the beginning of study followup and could be followed through at least age 30. They entered the period of risk for onset of schizophrenia during the followup period. Because of their age at the end of the study period, cohort members born between 1965 and 1967 could not contribute observations in the oldest age categories.
Those born between 1959 and 1964 were ages 16-21 at the beginning of the study period. They had already passed unobserved through 1 or more years at risk of disorder. As a result, cases with onset in late adolescence among those born during these years had their onset before the study period and were underascertained. For this reason, age-specific rate analyses for ages 15-19 were restricted to birth years [1965] [1966] [1967] . Those bom between 1959 and 1964 contribute all observations over age 33.
Loss to Followup
. When a cohort member ended his or her membership in the Health Plan during the study period and no longer appeared in the membership registries, he or she was designated as a "loss to followup." The median time followed was 12.7 years. A comparison of the 4,487 present at the end of followup with the 7,607 who left the Health Plan before the end of the study period indicates few differences between the groups on a range of characteristics (table 2) . Among those who left the Health Plan, 11 percent left before age 20, 40 percent between ages 20 and 24, 28 percent between ages 25 and 29, and 21 percent at age 30 or older.
These limitations in completeness of followup arising from fit between birth years and study years as well as the loss to followup are taken into account in methods of data analysis and interpretation of results.
Data Analysis
For the computation of incidence rates and cumulative risk, the PDS Study cohort of 12,094 was used. The period of case ascertainment was restricted to years coinciding with study followup (January 1, 1981, to December 31, 1997), yielding a potential sample of 67 subjects for this analysis. From the total of 71 cases, 4 were ascertained by an early registry during 1976-1981 and are not used in the estimation of incidence (Susser et al., 
this issue).
Incidence Rates. The incidence rates were calculated as the ratio of the number of cases of schizophrenia (or SSD) to the person-days of observation. The computation of person-days was based on the assumption that all subjects were alive and at risk at all points before the last followup date (i.e., the end of membership or date of first treatment). On this basis, cases contributed person-days from age 15 to the onset of disorder (i.e., the date of index treatment). All noncases contributed person-days from age 15 through either their withdrawal from the Health Plan during the study period or the end of the study period if they were members of the Health Plan at that time.
Age-and sex-specific rates were computed for age categories 15-19, 20-24, 25-29, 30-34 , and 35-38 years. As noted above, cases among those born in [1959] [1960] [1961] [1962] [1963] [1964] were underascertained in the age category 15-19 years; therefore, age-and sex-specific incidence rates for this age category are based on the observation of subjects born in 1965-1967 only.
All rates were calculated for schizophrenia and for SSD. Although calculated in person-days, incidence rates are reported per 10,000 person-years for comparability to previous reports. Ninety-five percent confidence intervals for point estimates were calculated using bootstrap methods to take account of the nonindependence of observations introduced by sibships in the study group (Efron and Tibshirani 1993) .
Cumulative Risk. The estimator proposed by Kaplan and Meier (1958) was used to assess the risk of schizophrenia (or SSD). With this method, estimates of the cumulative probability of developing schizophrenia by specific ages were obtained. Cumulative risk estimates for the entire cohort incorporated the risk in the 15-19 age category that was estimated from subjects born in 1965-1967. Overall and sex-specific cumulative risk estimates are reported for ages 20, 25, 30, 35 , and 38 years. Cumulative risk estimates the probability of an individual developing schizophrenia over a specified period, in this case from age 15 to the specified age. The cumulative risk by age 25, then, is the individual's probability of having experi- 2 Maternal psychiatric complaints include any record of coded emotional problems abstracted from medical records or suicide attempt in the 6 months prior to last menstrual period or during any study pregnancy for the PDS Study subject's mother.
enced the onset of schizophrenia at any time on or after his or her 15th birthday and before his or her 25th birthday (i.e., during the 15-19 or 20-24 age categories).
Results
Rate and risk analyses were based on 62 cases. Incidence Rates. The age-and sex-specific incidence rates for schizophrenia and SSD are reported in tables 3 and 4. Peak incidence of schizophrenia was observed among men in the 15-19 age category and among women in the 25-29 age category. The schizophrenia incidence rates across the age categories observed were higher for men than women in all but one age group (25-29). A similar sex pattern was observed for SSD. Peak incidence was observed in the 15-19 age category among men and in the 25-29 age category among women. The contribution of schizophrenia specifically to the incidence of spectrum disorders declined with age; among women age 30-34, no cases of spectrum disorder were accounted for by cases of diagnosed schizophrenia.
Cumulative Risk. Table 5 shows the cumulative probability of developing schizophrenia and SSD by ages 20, 25, 30, 35, and 38 (i.e., the probability of a diagnosis before the given ages). By age 38, the overall cumulative risk of developing schizophrenia was 0.65 percent, and of SSD 1.03 percent. The cumulative risk for schizophrenia by age 38 among men was 0.93 percent and among women 0.35 percent. The cumulative risk for SSD by age 38 was 1.34 percent for men and 0.70 percent for women.
Discussion
This is one of the few studies to report the incidence of schizophrenia in a well-defined prospective cohort design. In many respects, the findings presented here are similar to those of previous studies. Notably, the sex pattern in onset is consistent with the most frequently observed pattern of age-and sex-specific incidence. Peak incidence of schizophrenia is at a younger age for men (15-19 years) than for women (25-29 years), and the incidence is higher for men than women over the ages examined.
There are also intriguing variations from some previous reports. One difference is the high incidence rates reported for men under age 30. In interpreting this finding, questions of method are paramount. For this reason, we review some of the critical issues and prior reports before discussing the implications of this finding.
Loss to
FoUowup. An overarching concern in longitudinal studies is the potential impact of losses to followup on the results. Here, losses to foUowup occurred in two periods: the first period includes CHDS birth cohort members lost to followup before January 1,1981; the second period includes losses to followup over the PDS Study period. At this time, we have no direct evidence regarding the psychiatric status of those lost to followup in either period.
Losses to followup of CHDS birth cohort members before 1981 represent selection into the PDS Study cohort and will affect incidence if related to risk of schizophrenia. If future cases were more likely to be included in the PDS Study cohort, rates would be biased upward; if they were less likely to be included, rates would be biased downward. Either of these biases could occur if either child or family characteristics were related to remaining in the Health Plan and risk of schizophrenia. Because most losses to followup during this phase took place before children reached age 10, it is unlikely that child characteristics influenced family membership in the Health Plan and subsequent inclusion in the PDS Study cohort With respect to family characteristics, parental psychiatric status could influence both continuing membership in the Health Plan and vulnerability to schizophrenia in the child. Although parental psychiatric diagnosis is not known, recorded maternal psychiatric complaints in the 6 months before and during any study pregnancy suggest that the mothers of those followed are similar to those not followed (see Susser et al., this issue) .
Similarly, losses to followup among PDS Study cohort members could influence findings if member characteristics related to risk of schizophrenia affected membership in the Health Plan during the study period. If those destined to become cases were more likely to remain in the Health Plan than noncases, or the reverse, rates could be biased. To examine the potential impact of losses to PDS Study followup, we compared subjects present at the end of the followup period with those withdrawing from the Health Plan before the end of the study period and found substantial similarity (table 2). To further examine the impact of losses, we recomputed incidence rates for those age groups in which followup was most complete (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , restricting the analysis to members born in 1961 or later who had experienced these ages entirely within the study period. The age-and sexspecific rates obtained were highly similar to those reported (table 6). In the absence of direct evidence, however, variable loss to followup of PDS Study cohort members during the study period in either direction cannot be entirely ruled out. Note.-IR = incidence rate; SSD = schizophrenia spectrum disorder.
Incidence Rates. In assessing where this evidence stands in relation to previous estimates of schizophrenia incidence, comparison with other studies must be made with caution. Interpretation of differences in rates must take into account differences in study design affecting both the numerator and denominator of the incidence rate. For the purpose of comparing findings, we have categorized studies reporting incidence or cumulative risk into three groups: (1) traditional studies in which cases are ascertained on first contact through either registries or more aggressive case finding, and the population at risk is considered to be the population living in the catchment area from which the cases apparently derive at the time of ascertainment (e.g., Jablensky et al. 1992; Kendell et al. 1993; Brewin et al. 1997) ; (2) record linkage studies in which cases are identified in psychiatric registries and linked to a population at risk defined by birth (or other) cohorts in birth records and registries (or other records such as military records) with variable information available on migration, mortality, and other types of loss to followup (e.g., Davidson et al. 1999; Suvisaari et al. 1999 ); and (3) studies, such as the present one, in which cases are identified among well-defined cohorts (primarily birth cohorts) and ongoing followup data are available (e.g., Jones et al. 1994; Rasanen et al. 1999) . The rates reported here for the PDS Study are higher than those reported by traditional studies. The benchmark World Health Organization (WHO) Ten Country Study findings (Jablensky et al. 1992 ) will stand as representative of this category (table 7) . Case ascertainment lasted 2 years for first contact patients with nonaffective psychosis. The youngest age group in this study is of comparable birth years to the earliest members of the PDS Study cohort. A comparison of WHO Ten Country Study incidence rates for schizophrenia "narrowly" defined (CAT-EGO S+) and the PDS Study rates for DSM-IV schizophrenia shows that the PDS Study estimates for men to age 30 all exceed those reported by the WHO study at any developed-country sites, whereas rates are similar for women in most age groups. A comparison of the WHO rates for schizophrenia "broadly" defined (CATEGO SPO, FRC) and PDS Study spectrum disorder rates follows a similar pattern. A more recent study replicating the WHO methods using ICD-10 diagnostic criteria-similar to DSM-IV-also reported incidence rates lower than those found in the PDS Study (Brewin et al. 1997) . It is therefore unlikely that diagnostic criteria account for the difference.
The descriptive dissimilarity of the PDS Study incidence rates and those reported in the WHO Ten Country Study could result from chance. The lower limits of 95 percent confidence intervals for those PDS Study age-sex point estimates which are notably elevated include the highest point estimates of the WHO developed-country sites. The descriptive differences between these reported rates for men are thus suggestive rather than definitive.
Descriptive comparison to record linkage and birth cohort studies presents a different picture. Here, the PDS Study incidence rates are similar to or lower than the two studies of these types reporting sex-and age-specific incidence rates. Both studies were conducted in Finland and examined cohorts of birth years 1954 -1965 (Suvisaari et al. 1999 ) and birth year 1966 (Rasanen et al. 1999 ) during late adolescence and early adulthood (table 8) .
Cumulative Risk. Again, after taking into account the age of the cohort, the cumulative risks in the PDS Study Note.-PDS -Prenatal Determinants of Schizophrenia (Study); SSD = schizophrenia spectrum dsorder; WHO = World Health Organization. 1 Range of Incidence rate point estimates reported for developed-country city sites: Honolulu, Moscow, Nagasaki, Aarhus, Dublin, and Nottingham. Data points extrapolated from published figures (Jablensky et al. 1992, pp. 48-50) and unpublished tables. Age-and sex-specific rate data are no longer available for precise confirmation. are rather higher than those reported by traditional studies (table 5) . The WHO Ten Country Study developed-country sites' range of cumulative risk estimates 15-54 years old for schizophrenia narrowly defined are 0.26-0.54 percent, and for schizophrenia broadly defined are 0.50-1.13 percent (Jablensky et al. 1992) . The PDS Study cumulative risk estimates are, on the other hand, more comparable to those reported for schizophrenia in the record linkage and birth cohort studies. These studies include a 1966 Finnish birth cohort in which the overall cumulative risk was 0.66 percent by age 27 (0.99% for men and 0.43% for women; Isohanni et al. 1997) , and a 1946 British birth cohort in which the overall cumulative risk was 0.63 percent by age 43 (0.88% for men and 0.44% for women; Jones et al. 1994) . Another finding of higher risk of schizophrenia is reported in this issue for a Philadelphia birth cohort contemporary to the PDS Study cohort (Cannon et al., this issue) . The reported cumulative risk of 0.52 percent in an Israeli military inductee cohort linkage study (Davidson et al. 1999 ) also conforms to this pattern.
Implications.
If not resulting from chance, different observed incidence rates may be interpreted as reflecting either real differences or artifact. The Finnish investigators, for instance, have interpreted their findings as suggesting high rates of schizophrenia in Finland. The present study could be taken to indicate a high rate of schizophrenia among men in Alameda County, California. Possible reasons as to why the higher rates are evident among men and not women include risk factors for schizophrenia more common among men (e.g., cannabis use; Andreasson et al. 1987) or risk factors to which men may be particularly vulnerable.
Taken together, these and other recent findings provide some support for the view that there is notable real variation across places in the incidence of schizophrenia. Although many have argued a priori that such variation must be present (Torrey 1989) , empirical studies of schizophrenia incidence have often failed to demonstrate this. Researchers have even disseminated the notion that schizophrenia is roughly constant over time and place, and this notion has entered the thinking of clinicians and the public. Recent reports from cohort studies may be seen as challenging this notion. If cohort effects are the principal sources of variation in incidence, variation may remain undetected in traditional incidence designs because traditional incidence studies reflect the mixed experiences of people of many different ages and birth years (Susser 1973; Rothman and Greenland 1998) .
The capacity to detect variation differs between birth cohort and traditional incidence designs. Birth cohort studies are best suited to detect generation or cohort effects, especially those that result from the influence of early life exposures. These are thought to be important in schizophrenia (Susser et al. 1999; Suvisaari et al. 1999) .
Nonetheless, estimates of schizophrenia incidence are known to be sensitive to methodological factors. Artifact should be among the uppermost concerns in evaluating or comparing incidence estimates. Not only case ascertainment strategies, which are, in part, dictated by the nature of the disease and its rarity but also changing diagnostic criteria (Nicole et al. 1992; Kendell et al. 1993; Castle et al. 1998 ) influence the number of cases reflected in the numerator of the incidence rate. Completeness of case ascertainment and diagnostic criteria, however, do not effectively account for the rate differences observed. Whereas the WHO study was based on first contact ascertaining both inpatient and outpatient cases, outpatient case ascertainment in the PDS Study was less complete and still PDS Study rates were higher. Of the Finnish studies, both were completely restricted to hospitalized cases (Suvisaari 1999; Rasanen et al. 1999) ; nevertheless, they also reported high incidence rates. As noted earlier, neither do differences in diagnosis provide an adequate explanation for the patterns observed.
Mortality and migration influence the denominator of the incidence rates (Castle et al. 1998) . In cohort studies the population at risk is well defined and fixed; the cases plainly derive from this population. Incidence is better measured in a fixed population. Higher incidence rates observed in the PDS Study and Finnish studies in comparison to traditional studies may be in part attributable to this fundamental difference. The similarity of cumulative incidence found in the 1946 British cohort to that found in the PDS Study and Finnish studies could be taken to further support this construal of the evidence.
Limitations. First, like virtually all other studies of schizophrenia incidence and risk, the PDS Study estimates are based on treated cases. To the extent that cases of schizophrenia remain untreated, underestimation of true incidence is inevitable.
Second, ascertainment of outpatient cases was limited. Even though multiple sources were used to identify potential cases with no record of psychiatric hospital admission, the outpatient and pharmacy registries were not in effect during the entire followup period. An underestimation of incidence and cumulative risk may have resulted.
Third, cohort members receiving psychiatric care without Health Plan support (i.e., not submitting claims) at non-Health Plan facilities would also have escaped detection. Most of these cases would be outpatients who elected to use personal resources. For these cases to completely escape detection, however, all psychiatric treatments must consistently occur outside the purview of the Health Plan.
Fourth, the impact of underascertainment on the ageand sex-specific incidence rate in the 15-19 age category was minimized in the analysis by restricting the analyses to birth years [1965] [1966] [1967] ; this reduction in sample may have produced anomalous rates. To assess the reasonableness of these rates, we examined rates for various ages between 15 and 19 in birth years where followup was feasible. We obtained similar rates for ages 16-19 among those bom in 1964-1967 (for men 8.9, and for women 1.1 per 10,000 person-years) and for ages 17-19 among those born in 1963-1967 (for men 6.2, and for women 1.1 per 10,000 person-years). These results indicate that sample restriction does not account for the high rates reported for men ages 15-19.
Fifth, rate inflation in the older age categories is also theoretically possible as a result of incomplete followup. Recurring or chronic cases with onset before the study period among those born in 1959-1964 may have been ascertained at later treatment during the study period, inflating rates in the older age categories. In these cases the age of index treatment within the study period would systematically overstate the age at onset The examination of case files, however, revealed only two cases among cases born in 1959-1964 where this may have occurred. Thus, deferred ascertainment had limited impact
Conclusion
The PDS Study data on incidence and risk of schizophrenia demonstrate both consistency with and variation from data of previous reports. The PDS Study is the first study to examine incidence and cumulative risk of DSM-IV schizophrenia in a U.S. cohort. While the sex pattern in onset conformed to the most commonly observed pattern, incidences for men under age 30 were higher than those reported by traditional incidence studies. These differences could result from chance, design effects, or true variation in risk over time and place, possibly arising from cohort effects. Takei, N.; Lewis, G.; Sham, PC; and Murray, R.M. Ageperiod-cohort analysis of the incidence of schizophrenia in Scotland. Psychological Medicine, 26:963-973, 1996. Takei, N.; Sham, PC; O'Callaghan, E.; Glover, G.; and Murray, R.M. Schizophrenia: Increased risk associated with winter and city birth-A case-control study in 12 regions within England and Wales. Journal of Epidemiology and Community Health, 49:106-107, 1995. Torrey, E.F. Schizophrenia: Fixed incidence or fixed thinking? Psychological Medicine, 19:285-287, 1989. Torrey, E.F., and Bowler, A. Geographical distribution of insanity in America: Evidence for an urban factor. Schizophrenia Bulletin, 16 (4) 
